

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Estimated average burden
 hours per response: 0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>PENDARVIS DAVID</u> (Last) (First) (Middle) <u>14040 DANIELSON STREET</u> (Street) <u>POWAY CA 92064</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>RESMED INC [RMD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) <u>Sr. VP, General Counsel</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/12/2009</u>	
6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
ResMed Common Stock	02/12/2009		S		952	D	\$42.3401	2,863.342	D	
ResMed Common Stock	02/12/2009		M		1	A	\$13.815	2,864.342	D	
ResMed Common Stock	02/12/2009		S		1	D	\$42.255	2,863.342	D	
ResMed Common Stock	02/12/2009		M		4,654	A	\$18.7	7,517.342	D	
ResMed Common Stock	02/12/2009		S		4,654	D	\$42.2394 ⁽²⁾	2,863.342	D	
ResMed Common Stock	02/12/2009		M		12,000	A	\$20.745	14,863.342	D	
ResMed Common Stock	02/12/2009		S		12,000	D	\$42.255 ⁽³⁾	2,863.342	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
ResMed Common Stock	\$13.815	02/12/2009		M			1	10/01/2003 ⁽¹⁾	10/01/2012	ResMed Common Stock	1	\$0	293,713	D	
ResMed Common Stock	\$18.7	02/12/2009		M			4,654	05/27/2004 ⁽¹⁾	05/27/2013	ResMed Common Stock	4,654	\$0	289,059	D	
ResMed Common Stock Options	\$20.745	02/12/2009		M			12,000	12/19/2004 ⁽¹⁾	12/19/2013	ResMed Common Stock	12,000	\$0	277,059	D	

Explanation of Responses:

1. Represents first date options become exercisable.

2. This transaction was executed in multiple trades at prices ranging from \$42.21 to \$42.31. The price reported above reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.

3. This transaction was executed in multiple trades at prices ranging from \$42.21 to \$42.35. The price reported above reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.

Remarks:David Pendarvis02/13/2009

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.